What question did this study set out to answer?

This research aims to uncover the roles of PTK2B and MAPK signaling in BRAF V600E glioma and how their co-targeting can enhance therapeutic efficacy.

Dual targeting of interlocked PTK2B and MAPK signaling triggers synergistic ferroptosis via autophagic flux disruption in BRAFV600E glioma

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial shows enhanced tumor cell death in BRAF V600E glioma by targeting PTK2B and MAPK, suggesting a novel therapeutic strategy.

This research aims to uncover the roles of PTK2B and MAPK signaling in BRAF V600E glioma and how their co-targeting can enhance therapeutic efficacy.
Identified PTK2B as a target using gene expression profiles and immunohistochemistry on glioma samples.
Conducted loss-of-function studies through PTK2B knockdown in DBTRG-05MG cells and Fak knockout in Drosophila.
Utilized RNA sequencing, proteomics, and various assays to investigate signaling mechanisms and effects on tumor survival.
PTK2B knockdown induced potent ferroptosis in glioma cells, with disrupted autophagic flux and endoplasmic reticulum stress.
Inhibition of both PTK2B and MAPK notably suppressed tumor growth in BRAF V600E glioma cell lines.
Co-targeting PTK2B and MAPK achieved a synergistic anti-tumor effect, overcoming therapeutic resistance.

Wang et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Randomized trial shows enhanced tumor cell death in BRAF V600E glioma by targeting PTK2B and MAPK, suggesting a novel therapeutic strategy.